HFpEF Biomarker Study: Serum Levels of NT-proBNP, DLK-1, PSP-D, and PCSK-9 in 88 Subjects

58 HFpEF patients and 30 healthy controls were analyzed using Olink proteomics technology. The study, authored by Liu Xiaobin and last updated in April 2026, evaluates the diagnostic performance of four serum biomarkers for heart failure with preserved ejection fraction. The combined detection of NT-proBNP, DLK-1, PSP-D, and PCSK-9 achieved an AUC of 0.794.

Use Cases

• Train a binary classification model to diagnose HFpEF based on serum biomarker levels.
• Compare the diagnostic performance of individual biomarkers versus combinations using AUC metrics.
• Identify risk factors for HFpEF through regression analysis of biomarker data.

Strengths

• Includes results from 88 total subjects (58 patients, 30 controls).
• Reports specific AUC values for biomarker combinations, such as 0.794 for the four-marker panel.
• Uses advanced machine-learning algorithms for analysis, as stated in the description.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 20.4 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Serum samples analyzed using Olink proteomics technology.

Time Range

Prospective study; specific collection dates are not provided.

Freshness

Last updated 2026-04-14 05:38:45; freshness should be verified.

Geography

Geographic coverage is not specified in the provided metadata.